Authors
Parth Baberwal, Kapish Jain, Rakesh Kumar
Published in
PET clinics. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
[18F]fluorodeoxyglucose (FDG)-PET/CT informs decisions at almost every point in breast cancer care. It establishes the extent of disease at diagnosis and so determines whether treatment is delivered with curative or palliative intent. This review examines the biology that underlies FDG uptake and explains why uptake varies so markedly between molecular subtypes. It also sets out the evidence supporting FDG-PET/CT in staging and in therapeutic decision-making across chemotherapy, endocrine therapy, HER2-directed treatment, immunotherapy, and radiotherapy planning, before turning to the complimentary role of 18F-FDG PET/CT with theranostic agents.
PMID:
43009437
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0